Clairity raised $43 million to expand its AI mammography tool for predicting five-year breast cancer risk.
Key Details
- 1Clairity, founded in 2020 by Dr. Constance Lehman of Mass General, focuses on AI for breast cancer risk assessment.
- 2The company secured $43 million in Series B funding led by Ace Global Equity and Santé Ventures, with support from the Breast Cancer Research Foundation.
- 3Clairity Breast is the first AI tool to predict five-year breast cancer risk from standard mammograms.
- 4The product received FDA de novo authorization in May 2024.
- 5New funds will support commercialization and partnership expansion.
Why It Matters
Clairity's advancements could lead to earlier detection and prevention strategies using existing mammography infrastructure, potentially improving patient outcomes. The funding and FDA approval mark important milestones for AI adoption in radiology.
Source
Radiology Business
Related News
•AuntMinnie
AI Advances in Breast Cancer Risk, CEUS Training Updates, and Imaging AI Variability
This week's top radiology news reviews AI advances in breast and lung cancer risk prediction, new CEUS training standards, and prostate screening updates with imaging modalities.
•AuntMinnie
Mammography AI Model Outperforms Rivals for 10-Year Breast Cancer Risk
A new mammography-based AI model predicts 10-year breast cancer risk more accurately than established clinical and AI models.
•Radiology Business
SimonMed Imaging Introduces Paid AI Add-Ons for Routine Exams
SimonMed Imaging is launching new AI-powered elective services for routine imaging exams with additional out-of-pocket costs for patients.